Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis — Thomas G. Martin (2021) | RDL Network
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis
Thomas G. Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach, Michèle Cavo, Philippe Moreau, Meletios A Dimopoulos, Kwee Yong, Christina Tekle, Meredith C. Foster, Yvonne Barnes, Marie‐Laure Risse, Joseph Mıkhael
Marcelo Capra, Thomas G. Martin, Philippe Moreau, Ross Baker, Luděk Pour, Chang‐Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie‐Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos
Marcelo Capra, Thomas G. Martin, Philippe Moreau, Ross Baker, Luděk Pour, Chang‐Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie‐Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos
Ecenur Guder Arslan, Kwee Yong, T. John Martin, Meletios A Dimopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Philippe Moreau
Discussion(0)
No comments yet. Be the first to comment.